摘要
为评价司帕沙星对男性非淋球菌性尿道炎的治疗作用 ,将 16 0例男性非淋球菌性尿道炎患者随机分为两组 ,每组各 80例 ,分别采用司帕沙星 (2 0 0 mg,每天一次 )和米诺环素 (10 0 mg,每天 2次 )治疗 ,疗程均为 14d。结果 ,司帕沙星组与米诺环素组临床总有效率分别为 88.8%、91.3% ,对沙眼衣原体性尿道炎有效率分别为 93.8%、96 .0 % ,对解脲尿枝原体性尿道炎有效率分别为 78.1%、83.3% ,以上结果统计学均无显著性差异 ;药敏试验显示沙眼衣原体对司帕沙星与米诺环素敏感率分别为 94.9%、96 .9% ,解脲尿枝原体对两者敏感率分别为 81.9%、87.1% ,两组数据统计学无显著差异 ;两组不良反应发生率分别为 6 .3%、8.8% ,无显著差异 (P>0 .0 5 ) ,提示司帕沙星是一个高效、安全的抗菌药物 ,治疗非淋球菌性尿道炎疗效确切 。
To study the therapeutic effects of sparfloxacin on treating male nongonococcal urethritis. 160 male nongonococcal were randomly divided into two groups. One group ( n =80) was treated with sparflo xacin 200mg. po, qd for 14d, the other group ( n =80)was treated with minocycline 100mg, po, bid for 14d. The total effective rates were 88.8% in sparfloxacin group, and 91.3% in minocycline group, P >0.05. The sensitivity rates of Chlamydia trachomatis to sparfloxacin and minocycline were 94.9% and 96.9%, respec tively , P >0.05. The sensitivity rates of Ureaplasma urealyticum to sparfloxacin and minocyline were 81.8% and 87.1%, respectively, P >0.05. The adverse reaction rates of sparfloxacin and minocycline were 6.3% and 8.8%, respectively, P >0.05. Conclusion: Sparfloxacin is an effective and safe antibiotic in treating male nongococcal urethritis, it may become one of the first line drugs for this disease.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2001年第5期385-386,394,共3页
Chinese Journal of Antibiotics
